 "Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma")
The government on Tuesday cleared the air on the restricted emergency use approval granted to two Covid-19 vaccines — Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin — as the debate heats up over the move.
While Balram Bhargava, director general of the Indian Council of Medical Research (ICMR), defended the approval by the Indian regulator based on safety and immunogenicity data, the minutes of the meeting of the Subject Expert Committee (SEC) that recommended the approval were also made public.
This comes after experts raised questions over the approvals, especially for Covaxin, which is yet to generate and
